Thursday, September 14, 2023
News Health
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer

September 12, 2023
in Health News
Share on FacebookShare on Twitter


SINGAPORE — Treatment with osimertinib (Tagrisso) plus chemotherapy reduced the risk of disease progression or death by 38% compared with osimertinib monotherapy in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), according to data from a phase III trial.

Interim results from the FLAURA2 study showed that investigator-assessed median progression-free survival (PFS) improved by 8.8 months with osimertinib plus pemetrexed and platinum chemotherapy versus the EGFR inhibitor alone (25.5 months vs 16.7 months; HR 0.62, 95% CI 0.49-0.79, P

One- and 2-year PFS rates were 80% and 57%, respectively, in the combination arm versus 66%% and 41% in the monotherapy arm. Results were similar on blinded independent central review.

“Based on these findings, osimertinib plus platinum-pemetrexed offers a new first-line treatment option for patients with advanced EGFR-mutant advanced lung cancer,” Jänne said during a presentation at the World Conference on Lung Cancer.

Currently, EGFR-tyrosine kinase inhibitors (TKIs) are the standard of care for patients with advanced EGFR-mutant NSCLC, Jänne pointed out, with osimertinib — a third-generation TKI — the preferred first-line treatment based on the prior FLAURA trial, which demonstrated the superiority of osimertinib in PFS and overall survival (OS) compared with earlier-generation EGFR inhibitors.

“Despite osimertinib’s efficacy, most patients will, unfortunately, develop disease progression at some point during the course of their treatment,” Jänne said. However, he pointed out that even studies of first-generation EGFR-TKIs combined with chemotherapy have shown enhanced efficacy. Thus, the rationale for evaluating osimertinib and chemotherapy in this setting.

Jänne reported the PFS benefit was consistent across all predefined subsets.

Patients with central nervous system (CNS) metastases at baseline achieved a median investigator-assessed PFS of 24.9 months with the combination versus 13.8 months with osimertinib monotherapy (HR 0.47, 95% CI 0.33-0.66). In patients without CNS metastases, median PFS was 27.6 months versus 21 months (HR 0.75, 95% CI 0.55-1.03), respectively.

A PFS benefit was also seen in patients harboring common EGFR mutations. Those with an EGFR exon 19 deletion type had a median PFS of 27.9 months with the combination versus 19.4 months with monotherapy (HR 0.60, 05% CI 0.44-0.83), while those with exon 21 (L858R) mutations had a median PFS of 24.7 months and 13.9 months, respectively (HR 0.63, 95% CI 0.44-0.90).

Median OS data and time to second PFS were immature at the time of this analysis.

Discussant Yi-Long Wu, MD, of Guangdong Provincial People’s Hospital in Guangzhou, China, said that mature OS results are needed before determining whether the FLAURA2 model should become the standard of care in the first line for advanced EGFR-mutant NSCLC, and that currently it “may be” an option in that setting.

However, he added that it “should” become a first-line option for special subgroups of patients, such as those with brain metastases or exon 21 mutations.

The median duration of osimertinib exposure was 22.3 months in the combination arm and 19.3 months in the monotherapy arm. Patients in the combination arm received a median of 12 cycles of pemetrexed, while 77% of the patients completed four cycles of platinum-based chemotherapy with either cisplatin or carboplatin.

Most common adverse events (AEs) in the combination arm were related to chemotherapy, including neutropenia and thrombocytopenia, Jänne said. “There were no common grade 4 AEs in the monotherapy arm.”

“One of the questions that arises is that when you do combination therapies, are you going to increase toxicities such as interstitial lung disease, which can be seen with osimertinib?” Jänne pointed out. Here, in this trial, there was no difference in the incidence of interstitial lung disease between groups (eight cases in the combination arm and 10 in the monotherapy arm).

For the study, 557 patients were randomized 1:1 to osimertinib plus chemotherapy (osimertinib 80 mg once daily plus pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin AUC5 for four cycles) followed by maintenance osimertinib plus pemetrexed or osimertinib monotherapy until disease progression/discontinuation.

A majority of patients in the study were female, with a median age of 61-62 years. Jänne noted that about 40% of patients in each group had CNS metastases.

Ongoing analyses from the trial include CNS response and progression (per central review), patient-reported outcomes, post-progression endpoints, and circulating tumor DNA analyses, Jänne noted.

  • author['full_name']

    Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Disclosures

The study was funded by AstraZeneca.

Janne reported relationships with Astellas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, PUMA, Revolution Medicines, Takeda Oncology, ACEA Biosciences, Araxes, Bayer, Chugai Pharmaceuticals, Eisai, Ignyta, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax, Voronoi, Biocartis, Mirati Therapeutics, Transcenta, Gatekeeper Pharmaceuticals, and Labcorp.

Primary Source

World Conference on Lung Cancer

Source Reference: Janne P, et al “Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2)” WCLC 2023; Abstract PL03.13



Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/106299

Author :

Publish date : 2023-09-12 14:07:33

Copyright for syndicated content belongs to the linked Source.
Previous Post

12 Steps to Closing Your Practice Without Problems

Next Post

Sedentary Lifestyle Tied to Increased Dementia Risk

Related Posts

Health News

New treatment for migraine attacks on NHS to benefit thousands

September 14, 2023
Health News

Taking Medication for High Blood Pressure Can Drop Risk

September 13, 2023
Health News

France sets out plan to ban disposable vapes

September 13, 2023
Health News

No Benefit in Hospitalized COVID-19

September 13, 2023
Health News

Why Ice-T Wants You To Get Your Flu Shot This Fall

September 13, 2023
Health News

Sitting 10 Hours or More a Day May Increase Your Risk

September 13, 2023
Load More

Best Free Tranny Porn Porn Online

September 14, 2023

New treatment for migraine attacks on NHS to benefit thousands

September 14, 2023

Taking Medication for High Blood Pressure Can Drop Risk

September 13, 2023

France sets out plan to ban disposable vapes

September 13, 2023

No Benefit in Hospitalized COVID-19

September 13, 2023

Why Ice-T Wants You To Get Your Flu Shot This Fall

September 13, 2023

Sitting 10 Hours or More a Day May Increase Your Risk

September 13, 2023

CDC Recommends Updated COVID Shots to Target New Coronavirus Variants

September 13, 2023
Load More

Categories

Tags

curcumin (2) diet (2) Keto (2)

Archives

September 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
« Aug    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version

Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer- https://france-restos.com   https://casques-audio.com   https://deguisementdiscount.com   https://www.village-global.com   https://www.pushkar-india.com/   https://materiel-camping.info   https://www.politique-france.com   https://www.atelier-aquariophilie.com   -/- Demystifying Breast Illness Markers | RadioGraphics – RSNA Publications On-line   Les Meilleurs Vêtements « Shorty Femme » pour un Confort Absolu   Des nouvelles de la Nintendo Switch 2, le vélo révolutionnaire de Decathlon est là et un outil pour neutraliser les iPhone – Tech’spresso   -*- L’Arbre Vert Liquide de Rinçage Lave Vaisselle 750 ml Lot de 4   Soldes été 2023 : profitez des meilleures promos tech sur les plus grandes marques   */* Grooves basse & batterie (1 Livre + 1 CD)   Demystifying Breast Illness Markers | RadioGraphics – RSNA Publications On-line   Motorsport news | IndyCar legend Will Power nearly quit for fear of sick wife’s death – WWOS   * Fogo De Chão to open second New Jersey restaurant – Verdict Foodservice   Mayor bids to block pension of rapist ex-Met Police officer   Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer *Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer

NEWSHEALTH : Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer